Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Renal artery stenting for atherosclerotic renal artery stenosis: A review of contemporary data
Andrew E Warfield, Christopher S Morris, Anant D Bhave, Geoffrey M Scriver, Alan Massouh, Joshua Kallen, Bill S Majdalany, Department of Radiology, University of Vermont Medical Center, Burlington, VT 05401, United States
Richard T Solomon, Department of Nephrology, University of Vermont Medical Center, Burlington, VT 05401, United States
Author contributions: Warfield AE, Morris CS, and Majdalany BS contributed to concept, data collection and analysis; Warfield AE and Majdalany BS contributed to first draft and revision; Bhave AD, Scriver GM, Massouh A, Kallen J, and Solomon RT contributed to manuscript editing. All authors have read and approved the final manuscript.
AI contribution statement: No AI tools were used in the preparation of this manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Bill S Majdalany, MD, FSIR, Professor, Department of Radiology, University of Vermont Medical Center, 111 Colchester Avenue Patrick 127, Burlington, VT 05401, United States. bill.majdalany@uvmhealth.org
Received: June 18, 2026
Revised: July 10, 2026
Accepted: July 28, 2026
Published online: September 25, 2026
Processing time: 57 Days and 6.2 Hours
Revised: July 10, 2026
Accepted: July 28, 2026
Published online: September 25, 2026
Processing time: 57 Days and 6.2 Hours
Core Tip
Core Tip: Patients likely to benefit from renal artery stenting are those with severe anatomic renovascular disease (stenosis > 80% and especially > 90% often bilaterally or in a single functioning kidney) and severe manifestations of that disease (high systolic and diastolic blood pressure despite at least 3 medications, rapidly declining kidney function with low levels of proteinuria, or flash pulmonary edema without other pathophysiologic explanations. These patients were not included in prior randomized controlled trials and represent a high-risk subset of patients with atherosclerotic renovascular stenosis. Survival benefits may be achieved especially in patients stented for rapidly declining kidney function.